1997 was a stellar year for those making money off of the dying.

Bristol-Myers Squibb raked in over half a billion dollars off of AIDS. Burroughs-Wellcome continues to recover from that untimely setback called Concorde, pulling in profits surpassing their pre-Concorde level.

Wellcome is expected to pile up as much as $2 billion annually from sales of 3TC. The money is so good that companies are coming out of nowhere and expecting to take in huge profits off of the mouths labeled as HIV-positive and so hungry for anything that Science tells them has potential.

Profits to die for: a stockholders dream.